Ukraine HIV Therapeutics Market Analysis Report [2022-30]

Ukraine HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Ukraine HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Lekhim, Darnitsa, and Farmak. The market is driven by government policies and initiatives for the management of HIV infections in the country amidst the war situation. The HIV therapeutics market in Ukraine is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10UAPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Ukraine AUTHOR: Dr. Vishwa Modhia

Buy Now

Ukraine HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Ukraine HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Ukraine is an Eastern European country bordered by the Black Sea and the Sea of Azov. According to the most recent WHO data, HIV/AIDS-related deaths in Ukraine reached 3100 in 2020. With an age-adjusted death rate of 11.51 per 100,000 people, Ukraine ranks 55th in the world. In 2020, the adult prevalence of HIV/AIDS in Ukraine was 1%, ranking 44th globally with 2,60,000 HIV cases.

According to Ministry of Health data, the Dnipropetrovsk region ranks first in Ukraine in terms of AIDS mortality and is one of the top three regions with the highest prevalence of HIV infections. Before the war, Ukraine was making good progress in its National AIDS response. The number of people living with HIV and receiving antiretroviral (ARV) treatment grew steadily, reaching 132,239 by the beginning of 2022. Ukraine spent 7.6% of its GDP on healthcare in 2019.

Market Dynamics

Market Growth Drivers

Ukraine was the only EECA country (Eastern European and Central Asian countries) where the government funded a basic package of HIV prevention services in key populations from the state budget. Ukraine has shown remarkable resilience in its HIV response. Today, thanks to partners such as the Global Fund and the United States President's Emergency Plan for AIDS Relief (PEPFAR), Ukraine has received enough ARV medicines to ensure that no one with HIV/AIDS is left behind. Due to these factors, once the situation improves, there are chances of growth of Ukraine HIV therapeutics market.

Market Restraints

More than 7.9 Mn Ukrainians have fled to other countries as a result of the war, while another 6.5 Mn are internally displaced within the country. Because of destruction or occupation, more than 30 medical institutions providing HIV services have ceased operations. Logistical chains were also broken. Due to the war crisis, many players will not enter the HIV therapeutics market in Ukraine.

Competitive Landscape

Key Players

Farmak (UKR)
Darnitsa (UKR)
Lekhim (UKR)
Arterium (UKR)
Gilead Sciences
AbbVie
Roche

Recent Notable Update

April 2022: President's Emergency Plan for AIDS Relief (PEPFAR) donated HIV medications such as ART are being distributed to Ukrainian refugees in Poland, the Czech Republic, and other European Union countries with the assistance of drugmaker ViiV Healthcare. PEPFAR has invested a total of $13 Mn in emergency funding over the last two months to procure 51 Mn doses of antiretroviral medications (ARVs), enough to meet the urgent treatment needs of Ukrainians living with HIV for up to a year. PEPFAR initially provided 18 Mn doses of the ARVs tenofovir, lamivudine, and dolutegravir (TLD). These medications are already being rapidly distributed to HIV-positive people across Ukraine.

Healthcare Regulations and Reimbursement Policies

In Ukraine, HIV therapeutics are regulated by the Ministry of Health's State Expert Center (SEC). The SEC is in charge of evaluating and approving new HIV drugs on the basis of quality, safety, and efficacy. HIV medications are considered prescription-only medications and must be administered by licensed pharmacies or healthcare facilities. The Ukrainian government provides free antiretroviral therapy to HIV patients and collaborates with international organizations to increase the availability and affordability of HIV treatments in the country.

HIV therapeutics are reimbursed through Ukraine's national health insurance system. Through the National AIDS and STI Control Program, the government provides free antiretroviral therapy to all people living with HIV, regardless of their legal or social status. The program covers the cost of HIV medications as well as laboratory tests, medical consultations, and other HIV-related services. Furthermore, international organizations such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria provide financial support to Ukraine's HIV response, which helps to ensure the country's HIV treatment availability and affordability.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.